Login to Your Account



Capricor phase II data peek clouds prospects for Janssen deal

By Michael Fitzhugh
Staff Writer

Friday, May 12, 2017

Disappointing interim trial data suggesting that Capricor Therapeutics Inc.'s lead candidate is unlikely to best a placebo in reducing scar size after heart attack dimmed expectations that Janssen Biotech Inc. would exercise its option to take an exclusive license on the cell therapy, sending Capricor's shares down 62 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription